Open Journal Systems

Effect of Herceptin Combined with Phryl on Serum Tumor Markers and Toxicities in Patients with Breast Cancer

Shibo Gao (The tenth People's Hospital of Shenyang City,Shenyang, China)

Abstract


Objective. To study the effect of Herceptin combined with Phryl on serum tumor markers and toxicities in patients with breast cancer. Methods. A total of 66 patients with breast cancer admitted from February 2019 to February 2020 were selected as the research objects. They were divided into two groups by random number table method, with 33 cases in each group. The control group was treated with Herceptin, and the observation group was treated with Fray on the basis of the control group. The levels of serum tumor markers [cancer antigen 15-3(CA15-3), cell protein 19(CYFRA21-1)] and toxic reactions were compared between the two groups before treatment and 4 weeks after treatment. Results. After 4 weeks of treatment, serum CA15-3 and CYFRA21-1 in both groups were lower than before treatment, and those in the observation group were lower than those in the control group, the difference was statistically significant (P < 0. 05). There was significant difference in the incidence of adverse reactions between the two groups (P < 0. 05). Conclusion Herceptin combined with Flux in the treatment of breast cancer patients can reduce the level of serum tumor markers, inhibit tumor growth, and reduce the risk of toxicity.


Keywords


Breast cancer; Fu rui; Herceptin; Tumor markers; Adverse reaction

Full Text:

PDF

References


Cheng XM, Liang ZJ. Pathogenesis of breast cancer associated with cerebral infarction [J]. Chinese Journal of Physologist's Advancement, 2018,41 (11) : 1038-1041.

Zeng Yali, Zeng Yanhua, Tan Chuang, et al. Correlation between chemotherapy-related cognitive impairment and self-efficacy in breast cancer patients [J]. Journal of Nursing Science, 20 1 7, 3 2 (2) : 9-1 2.

Wang Y, Wang Y, Wang Y, et al. Ovarian function inhibition in early breast cancer: a review [J]. Chinese Journal of Cancer, 2018,28 (11) : 871-880.

Han Si-Jia, Chiu Fang, Han Ye, et al. The protective effect of right promethimide on cardiotoxicity induced by anthracycline chemotherapy after breast cancer surgery [J]. Chinese Journal of Maternal and Child Health, 2017,28 (S1) : 169.

Sun Lini. The application of Herceptin in the treatment of metastatic breast cancer [J]. Chinese Journal of Cancer Prevention and Treatment, 2018,25 (2) : 44-45.

Li WK, Tang HF. Analysis of the effect of Herceptin combined with Phryl therapy on serum factor levels and blood routine in breast cancer patients. Analysis and Clinics of Label Vaccination, 2018,25 (2) : 211-214.



DOI: http://dx.doi.org/10.30564/amor.v6i3.276

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Shibo Gao

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.